Another reason for Zenith to get busy with a Nasdaq listing

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

masila

Rank: Vice President [?]

Points: 818 [?]

Votes: 16 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Another reason for Zenith to get busy with a Nasdaq listing

posted on Oct 03, 2016 12:47PM

This is an ETF that is focusing on cancer related therapies. Would be nice if they held a chunk of Zenith (if we ever get a listing).

http://www.businesswire.com/news/home/20151014005833/en/Market%E2%80%99s-Cancer-Immunotherapy-ETF-Launches